
Check-Cap Ltd. CHEK
Annual report 2024
added 03-07-2026
Check-Cap Ltd. Accounts Payables 2011-2026 | CHEK
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Check-Cap Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 952 K | 1.05 M | 862 K | 989 K | 1.11 M | 608 K | 393 K | 577 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.11 M | 393 K | 818 K |
Quarterly Accounts Payables Check-Cap Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 1.05 M | - | 922 K | - | 862 K | - | 643 K | - | 989 K | - | 855 K | - | 1.11 M | - | 531 K | - | 608 K | - | 549 K | - | 393 K | - | 491 K | - | 577 K | - | - | - | 333 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.11 M | 333 K | 708 K |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
446 M | $ 115.35 | -2.33 % | $ 35.1 B | ||
|
Anixa Biosciences
ANIX
|
165 K | $ 2.81 | -2.7 % | $ 91.2 K | ||
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
881 K | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 22.48 | -1.58 % | $ 234 M | ||
|
Bioventus
BVS
|
10.9 M | $ 8.45 | -7.14 % | $ 563 M | ||
|
Celcuity
CELC
|
9.37 M | $ 114.85 | -0.34 % | $ 4.53 B | ||
|
Castle Biosciences
CSTL
|
6.9 M | $ 27.23 | -2.44 % | $ 756 M | ||
|
Charles River Laboratories International
CRL
|
149 M | $ 175.23 | -3.37 % | $ 8.69 B | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
Co-Diagnostics
CODX
|
1.48 M | - | - | $ 79.8 M | ||
|
Fulgent Genetics
FLGT
|
18.4 M | $ 14.59 | 2.41 % | $ 441 M | ||
|
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
Biodesix
BDSX
|
2.19 M | $ 18.61 | 17.37 % | $ 2.41 B | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
Illumina
ILMN
|
221 M | $ 124.76 | -2.71 % | $ 19.8 B | ||
|
IQVIA Holdings
IQV
|
322 M | $ 175.33 | -1.8 % | $ 30.1 B | ||
|
BioNano Genomics
BNGO
|
6.96 M | $ 1.11 | -1.36 % | $ 1.41 M | ||
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | ||
|
Quest Diagnostics Incorporated
DGX
|
307 M | $ 199.8 | -2.07 % | $ 22.2 B | ||
|
Danaher Corporation
DHR
|
1.84 B | $ 195.75 | -2.99 % | $ 140 B | ||
|
IDEXX Laboratories
IDXX
|
110 M | $ 607.19 | -1.9 % | $ 48.8 B | ||
|
Exact Sciences Corporation
EXAS
|
176 M | $ 103.5 | 0.17 % | $ 19.5 B | ||
|
DarioHealth Corp.
DRIO
|
1.13 M | $ 9.69 | -3.0 % | $ 275 M | ||
|
Laboratory Corporation of America Holdings
LH
|
841 M | $ 269.52 | -2.34 % | $ 22.4 B | ||
|
DexCom
DXCM
|
344 M | $ 68.5 | -3.1 % | $ 26.7 B | ||
|
QIAGEN N.V.
QGEN
|
83.3 M | - | - | $ 10.6 B | ||
|
ICON Public Limited Company
ICLR
|
173 M | $ 107.08 | -3.19 % | $ 8.83 B | ||
|
Lantheus Holdings
LNTH
|
42.9 M | $ 72.86 | -4.53 % | $ 4.92 B | ||
|
CareDx, Inc
CDNA
|
9.99 M | $ 17.91 | -4.48 % | $ 954 M | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Mettler-Toledo International
MTD
|
267 M | $ 1 215.85 | -3.66 % | $ 25.1 B | ||
|
Myriad Genetics
MYGN
|
30 M | $ 5.15 | 0.29 % | $ 477 M | ||
|
NeoGenomics
NEO
|
23.1 M | $ 8.92 | -2.3 % | $ 1.14 B | ||
|
National Research Corporation
NRC
|
1.17 M | $ 14.48 | 3.13 % | $ 324 M | ||
|
Guardant Health
GH
|
54.4 M | $ 91.56 | -1.1 % | $ 11.5 B | ||
|
Natera
NTRA
|
31.1 M | $ 196.94 | -0.1 % | $ 19.4 B | ||
|
OPKO Health
OPK
|
47.1 M | $ 1.18 | 0.43 % | $ 819 M | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K |